Müzeyyen GÖNÜL, Hatice ATAŞ

6562

Increased Risk of Metabolic Syndrome in Patients with Vitiligo

Increased Risk of Metabolic Syndrome in Patients with Vitiligo

Background: Inflammatory and immune processes can be triggered in vitiligo due to a decreased number of melanocytes and their anti-inflammatory effects. Because of the systemic nature of vitiligo, metabolic abnormalities such as insulin resistance and lipid profile disturbances as well as skin involvement may be observed in vitiligo. Aims: To investigate the association between metabolic syndrome and vitiligo. Study Design: Case-control study. Methods: The demographic, clinical and laboratory features in the subjects were compared according to presence of vitiligo and metabolic syndrome [patients (n=63) vs. gender-age matched controls (n=65) and metabolic syndrome positive (n=38) vs. negative (n=90)]. A logistic regression analysis was also used. Results: We identified metabolic syndrome in 24 (38.1%) subjects with vitiligo and 14 (21.5%) subjects without vitiligo (p=0.04). Active vitiligo, segmental vitiligo, an increased duration of vitiligo and an increased percentage in the affected body surface area were determined to be independent predictors of metabolic syndrome [activity of vitiligo: p=0.012, OR (95% CI)=64.4 (2.5-1672); type of vitiligo: p=0.007, OR (95% CI)=215.1 (4.3-10725.8); duration of vitiligo: p=0.03, OR (95% CI)=1.4 (1.1-2.0); percentage of affected body surface area: p=0.07, OR (95% CI)=1.2 (0.98-1.5)]. Conclusion: The risk of developing metabolic syndrome is increased in patients with vitiligo. The poor clinical features of vitiligo, such as active, extended and segmental vitiligo with an increased duration of time, are independent predictors for developing metabolic syndrome.
PDF

___

  • Ezzedine K, Lim HW, Suzuki T, Katayama I, Hamzavi I, Lan CC, et al. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res 2012;25:1-13.
  • Anbar TS, Westerhof W, Abdel-Rahman AT, El-Khayyat MA. Evaluation of the effects of NB-UVB in both segmental and non-segmental vitiligo affecting different body sites. Photodermatol Photoimmunol Photomed 2006;22:157-63.
  • Xie H, Zhou F, Liu L, Zhu G, Li Q, Li C, et al. Vitiligo: How do oxidative stress-induced autoantigens trigger autoimmunity? J Dermatol Sci 2016;81:3-9.
  • Sabir AA, Bilbis LS, Saidu Y, Jimoh A, Iwuala SO, Isezuo SA, et al. Oxidative stress among subjects with metabolic syndrome in Sokoto, North-Western Nigeria. Niger J Clin Pract 2016;19:128-32.
  • Pietrzak A, Bartosinska J, Hercogova J, Lotti TM, Chodorowska G. Metabolic syndrome in vitiligo. Dermatol Ther 2012;25(Suppl 1):41-3.
  • Kadam DP, Suryakar AN, Ankush RD, Kadam CY, Deshpande KH. Role of oxidative stress in various stages of psoriasis. Indian J Clin Biochem 2010;25:388-92.
  • Page S, Chandhoke V, Baranova A. Melanin and melanogenesis in adipose tissue: possible mechanisms for abating oxidative stress and inflammation? Obes Rev 2011;12:21-31.
  • Zhou SS, Li D, Zhou YM, Cao JM. The skin function: a factor of anti- metabolic syndrome. Diabetol Metab Syndr 2012;4:15.
  • Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52.
  • Majumder PP, Nordlund JJ, Nath SK. Pattern of familial aggregation of vitiligo. Arch Dermatol 1993;129:994-8.
  • Ongenae K, Van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 2003;16:90-100.
  • Kemp EH, Waterman EA, Hawes BE, O'Neill K, Gottumukkala RV, Gawkrodger DJ, et al. The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo. J Clin Invest 2002;109:923-30.
  • Basak PY, Adiloglu AK, Ceyhan AM, Tas T, Akkaya VB. The role of helper and regulatory T cells in the pathogenesis of vitiligo. J Am Acad Dermatol 2009;60:256-60.
  • Im S, Hann SK, Kim HI, Kim NS, Park YK. Biologic characteristics of cultured human vitiligo melanocytes. Int J Dermatol 1994;33:556-62.
  • Morrone A, Picardo M, de Luca C, Terminali O, Passi S, Ippolito F. Catecholamines and vitiligo. Pigment Cell Res 1992;5:65-9.
  • Schallreuter KU, Wood JM. Free radical reduction in the human epidermis. Free Radic Biol Med 1989;6:519-32.
  • Grimes PE, Sevall JS, Vojdani A. Cytomegalovirus DNA identified in skin biopsy specimens of patients with vitiligo. J Am Acad Dermatol 1996;35:21-6.
  • Ataş H, Cemil BÇ, Gönül M, Baştürk E, Çiçek E. Serum levels of homocysteine, folate and vitamin B12 in patients with vitiligo before and after treatment with narrow band ultraviolet B phototherapy and in a group of controls. J Photochem Photobiol B 2015;148:174-80.
  • Pissios P, Ozcan U, Kokkotou E, Okada T, Liew CW, Liu S, et al. Melanin concentrating hormone is a novel regulator of islet function and growth. Diabetes 2007;56:311-9.
  • Eschwege E. [Metabolic syndrome: which definition(s) for which objective(s)?]. Ann Endocrinol (Paris) 2005;66:1S32-44.
  • Pietrzak A, Lecewicz-Torun B, Urban J. Comparison of serum lipid in girls affected with vitiligo and control group. Ann Univ Mariae Curie Sklodowska Med 2000;55:269-74.
  • Mahajan S, Koranne RV, Sharma SK. Cutaneous manifestation of diabetes mellitus. Indian J Dermatol Venereol Leprol 2003;69:105-8.
  • Karadag AS, Tutal E, Ertugrul DT. Insulin resistance is increased in patients with vitiligo. Acta Derm Venereol 2011;91:541-4.
  • Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9.
  • Kozan O, Oguz A, Erol C, Senocak M, Ongen Z, Abacı A, et al. Results of METSAR. Metabolic Syndrome Research Group. Antalya: XX. National Congress of Cardiology; 2004. Available from: http://www.metsend.org/ pdf/Metsar-metsend.pdfMetabolik
  • LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999;282:2340-6.
  • Noel M, Gagne C, Bergeron J, Jobin J, Poirier P. Positive pleiotropic effects of HMG-CoA reductase inhibitor on vitiligo. Lipids Health Dis 2004;3:7.
  • Niki E. Antioxidants: basic principles, emerging concepts, and problems. Biomed J 2014;37:106-11.
Balkan Medical Journal-Cover
  • ISSN: 2146-3123
  • Yayın Aralığı: 6
  • Başlangıç: 2015
  • Yayıncı: Galenos Yayınevi
Arşiv
Sayıdaki Diğer Makaleler

Influenza and Pneumonia Vaccination Rates and Factors Affecting Vaccination among Patients with Chronic Obstructive Pulmonary Disease

Aslı DİLEKTAŞLI GÖREK, Banu Musaffa SALEPÇİ, Mustafa DÜGER, Ülkü AKTÜRK AKA, Nagihan KOÇAK DURMUŞ, Nuray OKTAY, Hale TAŞYIKAN ARIK, Aysun ŞENGÜL

Lack of Association Between Toll-like Receptor 2 Polymorphisms (R753Q and A-16934T) and Atopic Dermatitis in Children from Thrace Region of Turkey

Hilmi TOZKIR, Mehtap YAZICIOĞLU, Hakan GÜRKAN, Adnan GÖRGÜLÜ, Ceren CAN, Necdet Hilmi SÜT

Hyoid Bone and Thyroid Cartilage Metastases from Sigmoid Colon Adenocarcinoma: A Case Report

Djurdja BRACANOVİC, Vesna VUKOVİC, Aleksa JANOVİC, Davorin RADOSAVLJEVİC, Zoran RAKOCEVİC

Association Between the Inflammatory Biomarkers and Left Ventricular Systolic Dysfunction in Patients with Exacerbations of Chronic Obstructive Pulmonary Disease

Ljiljana ANDRİJEVİC, Senka MİLUTİNOV, Ilija ANDRİJEVİC, Daniela JOKİC, Marija VUKOJA

Normal and Tumour Tissue mRNA Expressions of Telomerase Complex Genes in Several Types of Cancer

Ülkü ARSLAN YALÇINTAŞ, Emel ÇALIŞKAN CAN, M. Can ATALAY, Ece Miser SALİHOĞLU, H. Bolkan ŞİMŞEK, Sevgi AKAYDIN YARDIM

Salivary Gland Choristoma of the Larynx

Recep BEDİR, Engin DURSUN, İbrahim ŞEHİTOĞLU, Rukiye YILMAZ

Increased Risk of Metabolic Syndrome in Patients with Vitiligo

Müzeyyen GÖNÜL, Hatice ATAŞ

Transpulmonary Hypothermia with Cooled Oxygen Inhalation Shows Promising Results as a Novel Hypothermia Technique

Orhan ÇINAR, Yahya Ayhan ACAR, Banu YILMAZ KARAKUŞ, Duygu Sultan ÇELİK, Aylin HAKLIGÖR, Hatice TOPÇU, Şule ÖZSOY, Erdem ÇEVİK

Solitary Fibrous Tumors of Chest: Another Look with the Oncologic Perspective

Mert SAYNAK, Dilruba OKUMUŞ, Nirmal K. VEERAMACHANENİ, Jessica L. HUBBS, Lawrence B. MARKS

Amoxycillin and Metronidazole Therapy for Helicobacter pylori Eradication: A 10-Year Trend in Turin, Italy

Davide Giuseppe RİBALDONE, Marco ASTEGİANO, Giorgio SARACCO, Rinaldo PELLİCANO